Developing a new treatment for cyanide poisoning using a drug and delivery device.
Optimization of a Combined Drug and Delivery Device for Treatment of Cyanide Poisoning
This study is working on a new way to quickly deliver a special antidote for cyanide poisoning using a handy autoinjector, which could help people in emergencies, like during a terrorist attack.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-10696942 on NIH RePORTER |
What this research studies
This research focuses on creating an effective combination of a drug and a delivery device to treat cyanide poisoning, particularly in the event of a terrorist attack. The project aims to optimize the delivery of sulfanegen, a rapidly acting antidote, using a customized autoinjector designed by Windgap Medical. The research includes testing the drug's effectiveness and safety in animal models before moving towards clinical trials and seeking FDA approval. Patients who may be exposed to cyanide in emergencies could benefit from this innovative treatment approach.
Who could benefit from this research
Good fit: Ideal candidates for this research would include individuals at risk of cyanide exposure, such as first responders or those in high-risk environments.
Not a fit: Patients who are not at risk of cyanide exposure or those with contraindications to the drug sulfanegen may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a rapid and effective treatment option for individuals exposed to cyanide, potentially saving lives in critical situations.
How similar studies have performed: Previous research has shown promise in using similar drug delivery approaches for emergency treatments, indicating potential for success in this novel application.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Wang, Zhengqiang — University of Minnesota
- Study coordinator: Wang, Zhengqiang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.